2024
Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort
Jaber Chehayeb R, Singh J, Matute-Martinez C, Chen N, Guajardo A, Lin D, Jayakrishnan R, Christofides A, Leveille E, Im Y, Biancon G, VanOudenhove J, Ibrahim E, Ardasheva A, Jha A, Hwa J, Halene S, Kwan J. Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort. Cardio-Oncology 2024, 10: 84. PMID: 39587635, PMCID: PMC11590368, DOI: 10.1186/s40959-024-00289-z.Peer-Reviewed Original ResearchImmune checkpoint inhibitor myocarditisImmune checkpoint inhibitorsImmune checkpoint inhibitor useICI-myocarditisIndeterminate potentialProspective studyImmune checkpoint inhibitor therapyCancer therapyClonal hematopoiesis of indeterminate potentialCancer treated with immunotherapyIncreased T cell activationObstructive coronary artery diseaseMultivariate competing risk analysisCardiotoxic cancer therapyRisks Cox regressionAssociated with increased riskIncreased all-cause mortalityPatient co-morbiditiesRisk of cardiomyopathyT cell activationCompeting risk analysisCoronary artery calcificationCoronary artery diseaseAll-cause mortalityHeart failure patientsMitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Hong Y, Pasca S, Shi W, Puiu D, Lake N, Lek M, Ru M, Grove M, Prizment A, Joshu C, Platz E, Guallar E, Arking D, Gondek L. Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms. Nature Communications 2024, 15: 10133. PMID: 39578475, PMCID: PMC11584845, DOI: 10.1038/s41467-024-54443-3.Peer-Reviewed Original ResearchConceptsClonal hematopoiesis of indeterminate potentialClonal hematopoiesisVariant allele fractionHeteroplasmic variantsIndeterminate potentialMyeloid neoplasmsHeteroplasmyMultiple mutationsAllele fractionMutationsHigh-risk groupPathogenic risk factorsMarkersRisk score modelDeleteriousnessSpliceosomeHematologic malignanciesRisk stratificationNeoplasm developmentNeoplasmsNeoplasm incidenceRisk factorsVariantsClonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.Peer-Reviewed Original ResearchClonal hematopoiesis of indeterminate potentialClonal hematopoiesisClonal cytopeniaSomatic genetic alterationsTherapeutic targetStem/progenitor cell populationsRisk stratification toolBlood of individualsMyeloid malignanciesMyeloid neoplasmsHematologic malignanciesPotential therapeutic targetIndeterminate potentialRisk stratificationBlood countGenetic alterationsStratification toolClinical investigationNatural historyCell populationsCytopeniasMalignancyBloodRiskCytopenia(s
2023
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
Zekavat S, Viana-Huete V, Matesanz N, Jorshery S, Zuriaga M, Uddin M, Trinder M, Paruchuri K, Zorita V, Ferrer-Pérez A, Amorós-Pérez M, Kunderfranco P, Carriero R, Greco C, Aroca-Crevillen A, Hidalgo A, Damrauer S, Ballantyne C, Niroula A, Gibson C, Pirruccello J, Griffin G, Ebert B, Libby P, Fuster V, Zhao H, Ghassemi M, Natarajan P, Bick A, Fuster J, Klarin D. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nature Cardiovascular Research 2023, 2: 144-158. PMID: 36949957, DOI: 10.1038/s44161-022-00206-6.Peer-Reviewed Original ResearchPeripheral artery diseaseIncident peripheral artery diseaseArtery diseaseAtherosclerotic diseaseChimeric miceIncident atherosclerotic diseaseCoronary artery diseaseAortic plaque sizeAccumulation of macrophagesMass General Brigham BiobankEntire arterial systemWhole-exome sequencingDNA damage repair genesCause mortalityCoronary arteryHematologic malignanciesPlaque macrophagesClinical dataTransplantation strategiesArterial systemPlaque sizeAtherosclerosisClonal hematopoiesisDiseaseIndeterminate potential
2022
CHIPing away the progression potential of CHIP: A new reality in the making
Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: A new reality in the making. Blood Reviews 2022, 58: 101001. PMID: 35989137, DOI: 10.1016/j.blre.2022.101001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClonal hematopoiesisEffective preventive strategiesEvidence-based recommendationsClinical sequelaeInterventional trialsClinical outcomesClinical trialsPreventive strategiesInterventional strategiesProgression potentialClinical implicationsIndeterminate potentialTrialsMolecular mechanismsLatest updatesHematopoiesisUrgent need
2020
How I Diagnose Low-Grade Myelodysplastic Syndromes
Siddon AJ, Hasserjian RP. How I Diagnose Low-Grade Myelodysplastic Syndromes. American Journal Of Clinical Pathology 2020, 154: 5-14. PMID: 32458977, DOI: 10.1093/ajcp/aqaa046.Peer-Reviewed Original ResearchConceptsLow-grade myelodysplastic syndromesMyelodysplastic syndromeMorphologic dysplasiaPeripheral blood cytopeniasCauses of cytopeniaDifficult diagnostic dilemmaBone marrow morphologyClonal genetic abnormalitiesRole of pathologistsBlood cytopeniasPeripheral bloodClinical recordsDiagnostic dilemmaMarrow morphologySecondary causesAncillary studiesIneffective hematopoiesisMyeloid neoplasmsMDS casesClinical heterogeneityDiagnostic algorithmResults of cytogeneticsGenetic abnormalitiesClonal hematopoiesisIndeterminate potential
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply